Streck has introduced a new flow cytometry control, CD-Chex TdT Plus. It is the only commercially available flow cytometry control assayed for TdT, CD1a, CD34 and cCD3 in a single control.
CD-Chex TdT Plus can be used as quality control material for evaluating intracellular and surface antigens including CD1a, CD2, CD4, CD5, CD7, CD8, CD34, cytoplasmic CD3 and nuclear TdT (Terminal deoxynucleotidyl transferase). When stained with fluorescent antibodies and analyzed by flow cytometry, CD-Chex TdT Plus provides reference values for abnormal cells often found in certain types of hematopoietic neoplasms. CD-Chex TdT Plus is For Research Use Only. Not for use in diagnostic procedures.
CD-Chex TdT Plus offers 30-day open-vial stability and up to 90-day closed-vial stability. CD-Chex TdT Plus is designed for use on BD Biosciences and Beckman Coulter® flow cytometry systems. This control complements Strecks full line of flow cytometry controls.
About Streck, Inc.
Streck is an industry leader in the development and manufacturing of products for clinical and research laboratories. The companys pursuit of innovative solutions has produced an extensive list of patented products. Strecks core technology is cell stabilization; product lines support the fields of hematology, immunology and molecular diagnostics. For more information, visit www.streck.com.